The global market for Pulmonary Fibrosis Treatment was estimated at US$3.2 Billion in 2024 and is projected to reach US$4.2 Billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pulmonary Fibrosis Treatment market.
The global burden of IPF and other fibrotic interstitial lung diseases (ILDs) is increasing due to aging populations, environmental exposures, and comorbid conditions such as rheumatoid arthritis and systemic sclerosis. As understanding of fibrotic mechanisms improves, there is a growing consensus that antifibrotic therapies should be initiated earlier in the disease course to decelerate lung function loss. This has led to evolving guidelines by organizations such as the American Thoracic Society (ATS), advocating for routine pulmonary function monitoring and earlier access to therapeutic agents. As a result, the therapeutic landscape is transitioning from symptom management to disease-modifying interventions.
Beyond IPF, nintedanib has gained expanded indication for progressive fibrosing ILDs and systemic sclerosis-associated ILD. This reflects a broader trend in repositioning antifibrotics for multiple fibrotic pathologies. Clinical trials are now testing combination regimens, including the pairing of antifibrotics with immunomodulators, anti-cytokine therapies, and senolytic agents. Targeted molecules such as PLN-74809 (a dual integrin inhibitor by Pliant Therapeutics) and PRM-151 (ziltivekimab) are under development with the aim to interrupt fibroblast activation and ECM remodeling. Rare patient cohorts, such as pediatric fibrotic lung disease and post-COVID pulmonary fibrosis, are also gaining attention in pipeline diversification strategies.
Telehealth platforms and digital inhaler adherence tools are supporting chronic disease management, especially for patients in remote or underserved areas. Patient-reported outcome measures (PROMs) and mobile spirometry are increasingly integrated into longitudinal monitoring frameworks, allowing clinicians to tailor treatment regimens based on patient functionality and progression speed. Guidelines from organizations such as ATS, ERS, and NICE now emphasize multidisciplinary discussions (MDDs) and routine functional assessment every 3-6 months, facilitating treatment adjustment and timely escalation.
Furthermore, strategic collaborations, licensing deals, and acquisitions between biotechs and large pharma players are facilitating faster clinical development. Real-world evidence is increasingly being incorporated into market access and pricing strategies, enabling broader reimbursement of high-cost antifibrotics in emerging markets. Geographically, North America and Western Europe continue to lead in terms of diagnosis and therapy adoption, but Asia-Pacific markets are seeing rapid growth due to increasing awareness and evolving reimbursement policies.
Major market participants include Roche, Boehringer Ingelheim, FibroGen, Pliant Therapeutics, Galapagos NV, Bellerophon Therapeutics, and United Therapeutics. With the anticipated arrival of next-generation fibrosis inhibitors and companion diagnostics, the market is poised for long-term growth centered on precision therapy, earlier treatment initiation, and holistic patient care models.
Segments: Therapy Type (Monotherapy, Combination Therapy, Symptomatic Treatment); Indication (Idiopathic Pulmonary Fibrosis, Familial PF, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacy Distribution Channel)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Global Pulmonary Fibrosis Treatment Market - Key Trends & Drivers Summarized
Why Is Pulmonary Fibrosis Emerging as a High-Priority Target in Respiratory Therapeutics?
Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), has drawn increasing focus from pharmaceutical developers and healthcare systems due to its progressive, irreversible nature and poor long-term prognosis. The disease is characterized by scarring of lung tissues, leading to a steady decline in lung function, exercise capacity, and ultimately survival. IPF has a median survival time of three to five years post-diagnosis, and therapeutic innovation has been historically limited. However, rising diagnostic awareness, advanced imaging modalities, and biomarker-led stratification are facilitating earlier intervention and expanding the treatment-eligible patient pool.The global burden of IPF and other fibrotic interstitial lung diseases (ILDs) is increasing due to aging populations, environmental exposures, and comorbid conditions such as rheumatoid arthritis and systemic sclerosis. As understanding of fibrotic mechanisms improves, there is a growing consensus that antifibrotic therapies should be initiated earlier in the disease course to decelerate lung function loss. This has led to evolving guidelines by organizations such as the American Thoracic Society (ATS), advocating for routine pulmonary function monitoring and earlier access to therapeutic agents. As a result, the therapeutic landscape is transitioning from symptom management to disease-modifying interventions.
Which Drug Classes, Novel Mechanisms, and Patient Segments Are Shaping Market Development?
The current treatment landscape is dominated by two antifibrotic agents: pirfenidone (Esbriet) and nintedanib (Ofev). Both drugs received approval in the U.S., EU, and Asia-Pacific for IPF management and have demonstrated efficacy in slowing forced vital capacity (FVC) decline. Pirfenidone, an oral pyridone compound, exerts anti-inflammatory and antifibrotic effects by inhibiting TGF-β and other fibrogenic cytokines. Nintedanib, a tyrosine kinase inhibitor, targets pathways including PDGF, FGF, and VEGF. Both agents are associated with gastrointestinal side effects and require long-term compliance, yet remain the standard of care in most high-income countries.Beyond IPF, nintedanib has gained expanded indication for progressive fibrosing ILDs and systemic sclerosis-associated ILD. This reflects a broader trend in repositioning antifibrotics for multiple fibrotic pathologies. Clinical trials are now testing combination regimens, including the pairing of antifibrotics with immunomodulators, anti-cytokine therapies, and senolytic agents. Targeted molecules such as PLN-74809 (a dual integrin inhibitor by Pliant Therapeutics) and PRM-151 (ziltivekimab) are under development with the aim to interrupt fibroblast activation and ECM remodeling. Rare patient cohorts, such as pediatric fibrotic lung disease and post-COVID pulmonary fibrosis, are also gaining attention in pipeline diversification strategies.
How Are Diagnostics, Digital Tools, and Clinical Guidelines Impacting Treatment Uptake and Optimization?
Improved high-resolution computed tomography (HRCT), lung biopsy techniques, and digital auscultation tools are enhancing diagnostic accuracy and enabling stratification of fibrosis subtypes. The ability to distinguish IPF from other ILDs-such as hypersensitivity pneumonitis and nonspecific interstitial pneumonia-is critical, given treatment differences. AI-powered imaging analysis and machine learning tools are emerging as aids in diagnosing patterns such as usual interstitial pneumonia (UIP) on HRCT, which can inform treatment eligibility and trial recruitment.Telehealth platforms and digital inhaler adherence tools are supporting chronic disease management, especially for patients in remote or underserved areas. Patient-reported outcome measures (PROMs) and mobile spirometry are increasingly integrated into longitudinal monitoring frameworks, allowing clinicians to tailor treatment regimens based on patient functionality and progression speed. Guidelines from organizations such as ATS, ERS, and NICE now emphasize multidisciplinary discussions (MDDs) and routine functional assessment every 3-6 months, facilitating treatment adjustment and timely escalation.
What Factors Are Driving the Growth of the Global Pulmonary Fibrosis Treatment Market?
The growth in the global pulmonary fibrosis treatment market is driven by rising disease prevalence, expanding indications for antifibrotic therapies, and robust pipeline innovation across multiple fibrotic ILD subtypes. Pharmaceutical interest is further fueled by high unmet clinical needs, orphan drug incentives, and accelerated regulatory pathways in the U.S., EU, and Japan. As healthcare systems become more adept at early detection through pulmonology networks, the diagnosed and treated population base is expected to expand significantly.Furthermore, strategic collaborations, licensing deals, and acquisitions between biotechs and large pharma players are facilitating faster clinical development. Real-world evidence is increasingly being incorporated into market access and pricing strategies, enabling broader reimbursement of high-cost antifibrotics in emerging markets. Geographically, North America and Western Europe continue to lead in terms of diagnosis and therapy adoption, but Asia-Pacific markets are seeing rapid growth due to increasing awareness and evolving reimbursement policies.
Major market participants include Roche, Boehringer Ingelheim, FibroGen, Pliant Therapeutics, Galapagos NV, Bellerophon Therapeutics, and United Therapeutics. With the anticipated arrival of next-generation fibrosis inhibitors and companion diagnostics, the market is poised for long-term growth centered on precision therapy, earlier treatment initiation, and holistic patient care models.
Scope Of Study:
The report analyzes the Pulmonary Fibrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:Segments: Therapy Type (Monotherapy, Combination Therapy, Symptomatic Treatment); Indication (Idiopathic Pulmonary Fibrosis, Familial PF, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacy Distribution Channel)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Monotherapy segment, which is expected to reach US$2.7 Billion by 2030 with a CAGR of a 5.6%. The Combination Therapy segment is also set to grow at 4.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $859.7 Million in 2024, and China, forecasted to grow at an impressive 9.1% CAGR to reach $894.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Pulmonary Fibrosis Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pulmonary Fibrosis Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Pulmonary Fibrosis Treatment Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AstraZeneca PLC, Avalyn Pharma Inc., Biogen Inc., Boehringer Ingelheim, Bristol-Myers Squibb Company and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 43 companies featured in this Pulmonary Fibrosis Treatment market report include:
- AstraZeneca PLC
- Avalyn Pharma Inc.
- Biogen Inc.
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Cipla Inc.
- FibroGen, Inc.
- Galapagos NV
- Genentech (Roche)
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- MediciNova, Inc.
- Medtronic plc
- Merck & Co., Inc.
- Novartis AG
- Pliant Therapeutics Inc.
- Promedior, Inc.
- Roche Holding AG
- United Therapeutics Corporation
- Vicore Pharma AB
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Avalyn Pharma Inc.
- Biogen Inc.
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Cipla Inc.
- FibroGen, Inc.
- Galapagos NV
- Genentech (Roche)
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- MediciNova, Inc.
- Medtronic plc
- Merck & Co., Inc.
- Novartis AG
- Pliant Therapeutics Inc.
- Promedior, Inc.
- Roche Holding AG
- United Therapeutics Corporation
- Vicore Pharma AB
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 376 |
Published | July 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value in 2024 | 3.2 Billion |
Forecasted Market Value by 2030 | 4.2 Billion |
Compound Annual Growth Rate | 5.0% |
Regions Covered | Global |